Biltmore Family Office LLC Lowers Stake in Danaher Co. (NYSE:DHR)

by · The Cerbat Gem

Biltmore Family Office LLC trimmed its holdings in Danaher Co. (NYSE:DHR – Free Report) by 4.6% in the third quarter, according to its most recent disclosure with the SEC. The fund owned 1,727 shares of the conglomerate’s stock after selling 84 shares during the period. Biltmore Family Office LLC’s holdings in Danaher were worth $481,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also made changes to their positions in the business. CarsonAllaria Wealth Management Ltd. acquired a new stake in Danaher during the 2nd quarter worth approximately $25,000. nVerses Capital LLC purchased a new position in Danaher in the 2nd quarter valued at $25,000. MidAtlantic Capital Management Inc. purchased a new position in Danaher in the 3rd quarter valued at $40,000. MFA Wealth Advisors LLC purchased a new position in Danaher during the 2nd quarter worth $51,000. Finally, Financial Connections Group Inc. purchased a new position in Danaher during the 2nd quarter worth $51,000. 79.05% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Danaher

In other news, SVP Georgeann Couchara sold 952 shares of the company’s stock in a transaction dated Monday, August 26th. The shares were sold at an average price of $268.37, for a total transaction of $255,488.24. Following the completion of the transaction, the senior vice president now owns 4,212 shares of the company’s stock, valued at $1,130,374.44. This represents a 18.44 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 11.10% of the stock is currently owned by insiders.

Danaher Stock Performance

NYSE DHR opened at $234.76 on Friday. The company has a quick ratio of 1.01, a current ratio of 1.37 and a debt-to-equity ratio of 0.32. Danaher Co. has a fifty-two week low of $215.68 and a fifty-two week high of $281.70. The business has a fifty day moving average of $258.92 and a 200-day moving average of $259.96. The stock has a market cap of $169.56 billion, a price-to-earnings ratio of 44.80, a price-to-earnings-growth ratio of 4.25 and a beta of 0.85.

Danaher (NYSE:DHR – Get Free Report) last announced its earnings results on Tuesday, October 22nd. The conglomerate reported $1.71 earnings per share for the quarter, beating the consensus estimate of $1.57 by $0.14. Danaher had a net margin of 16.39% and a return on equity of 10.62%. The firm had revenue of $5.80 billion during the quarter, compared to the consensus estimate of $5.59 billion. During the same quarter in the previous year, the company posted $2.02 EPS. The firm’s revenue for the quarter was up 3.1% on a year-over-year basis. As a group, analysts predict that Danaher Co. will post 7.5 earnings per share for the current fiscal year.

Danaher Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Friday, October 25th. Shareholders of record on Friday, September 27th were paid a $0.27 dividend. The ex-dividend date was Friday, September 27th. This represents a $1.08 annualized dividend and a yield of 0.46%. Danaher’s payout ratio is currently 20.61%.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on DHR. Stifel Nicolaus boosted their price target on shares of Danaher from $250.00 to $265.00 and gave the stock a “hold” rating in a research note on Wednesday, October 23rd. Robert W. Baird dropped their target price on Danaher from $278.00 to $277.00 and set an “outperform” rating on the stock in a research report on Wednesday, October 23rd. Evercore ISI lifted their price target on Danaher from $275.00 to $278.00 and gave the company an “outperform” rating in a research note on Tuesday, October 1st. Royal Bank of Canada cut their price objective on Danaher from $333.00 to $311.00 and set an “outperform” rating for the company in a research report on Wednesday, October 23rd. Finally, Barclays decreased their target price on shares of Danaher from $285.00 to $275.00 and set an “equal weight” rating on the stock in a research report on Wednesday, October 23rd. Six research analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $287.16.

Check Out Our Latest Stock Report on DHR

About Danaher

(Free Report)

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.

Recommended Stories